Idea Rankings

Introduction

This page ranks therapeutic concepts and ideas for neurodegenerative diseases based on mechanistic strength, development feasibility, and clinical potential. [@cummings2024]

Top Alzheimer's Disease Ideas

Disease-Modifying (by mechanistic strength)

| Rank | Idea | Target | Evidence | Feasibility | [@kalia2023]
|------|------|--------|----------|-------------|
| 1 | Triple amyloid-[tau](/proteins/tau)-inflammation | Multiple | High | Moderate |
| 2 | APOE4-specific immunotherapy | Amyloid | High | High |
| 3 | Tau vaccination with adjuvant | Tau | Moderate | High |
| 4 | Synaptic regeneration | Neural repair | Low | Low |
| 5 | Metabolic enhancement | Mitochondria | Moderate | Moderate |

Symptomatic (by efficacy)

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | GLP-1/GIP dual agonism | Metabolism | High | High |
| 2 | AMPA modulators | Glutamate | Moderate | High |
| 3 | PDE inhibitors | cAMP | Moderate | Moderate |
| 4 | 5-HT6 antagonists | Serotonin | Moderate | Moderate |

Top Parkinson's Disease Ideas

Disease-Modifying

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | Alpha-synuclein aggregation inhibitor | α-syn | Moderate | High |
| 2 | GBA gene therapy augmentation | Glucocerebrosidase | Moderate | Moderate |
| 3 | LRRK2 kinase inhibitor | LRRK2 | High | High |
| 4 | Microglial modulation | Neuroinflammation | Moderate | Moderate |

Symptomatic

Introduction

This page ranks therapeutic concepts and ideas for neurodegenerative diseases based on mechanistic strength, development feasibility, and clinical potential. [@cummings2024]

Top Alzheimer's Disease Ideas

Disease-Modifying (by mechanistic strength)

| Rank | Idea | Target | Evidence | Feasibility | [@kalia2023]
|------|------|--------|----------|-------------|
| 1 | Triple amyloid-[tau](/proteins/tau)-inflammation | Multiple | High | Moderate |
| 2 | APOE4-specific immunotherapy | Amyloid | High | High |
| 3 | Tau vaccination with adjuvant | Tau | Moderate | High |
| 4 | Synaptic regeneration | Neural repair | Low | Low |
| 5 | Metabolic enhancement | Mitochondria | Moderate | Moderate |

Symptomatic (by efficacy)

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | GLP-1/GIP dual agonism | Metabolism | High | High |
| 2 | AMPA modulators | Glutamate | Moderate | High |
| 3 | PDE inhibitors | cAMP | Moderate | Moderate |
| 4 | 5-HT6 antagonists | Serotonin | Moderate | Moderate |

Top Parkinson's Disease Ideas

Disease-Modifying

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | Alpha-synuclein aggregation inhibitor | α-syn | Moderate | High |
| 2 | GBA gene therapy augmentation | Glucocerebrosidase | Moderate | Moderate |
| 3 | LRRK2 kinase inhibitor | LRRK2 | High | High |
| 4 | Microglial modulation | Neuroinflammation | Moderate | Moderate |

Symptomatic

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | Long-acting dopamine agonist | Dopamine | High | High |
| 2 | Adenosine A2A antagonist | adenosine | Moderate | High |
| 3 | Levodopa-sparing combinations | Multiple | Moderate | Moderate |

Top ALS Ideas

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | SOD1 gene silencing | SOD1 | High | High |
| 2 | [C9orf72](/entities/c9orf72)-targeted ASO | C9orf72 | High | High |
| 3 | Antisense for FUS | FUS | Moderate | High |
| 4 | Muscle strengtheners | Muscle | Moderate | Moderate |
| 5 | Metabolic modulators | Energy | Low | Moderate |

Innovation Rankings

Novel Mechanisms

| Rank | Idea | Innovation | Risk |
|------|------|------------|------|
| 1 | Epigenetic modulation | Very High | High |
| 2 | [Microbiome](/entities/microbiome)-based therapy | High | Moderate |
| 3 | Exosome therapeutics | High | Moderate |
| 4 | Optogenetic approaches | Very High | Very High |
| 5 | Gene editing (CRISPR) | Very High | High |

Repurposing Potential

| Rank | Drug | Original Use | Repurpose Score |
|------|------|--------------|-----------------|
| 1 | Metformin | Diabetes | 85 |
| 2 | Ibuprofen | Pain/ inflammation | 80 |
| 3 | Saracatinib | Cancer | 75 |
| 4 | Losartan | Hypertension | 70 |
| 5 | Valproic acid | Epilepsy | 65 |

Development Readiness

Near-Term Opportunities

Mid-Term Opportunities

Long-Term Opportunities

Patient Impact Potential

| Idea | Impact | Timeline | Unmet Need |
|------|--------|----------|------------|
| Disease modification | Very High | 5-10 years | High |
| Early detection + treatment | Very High | 3-5 years | Very High |
| Symptom control | Moderate | 1-3 years | High |
| Prevention | Very High | 10+ years | Very High |

Related Pages

• [Ideas Index](/ideas)
• [Ideas Overview](/ideas/overview)
• [Treatments](/therapeutics)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-Links

Disease Pathways

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary target disease
• [Parkinson's Disease](/diseases/parkinsons-disease) — Primary target disease
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Primary target disease

Key Therapeutic Targets

• [Amyloid Beta](/proteins/amyloid-beta) — AD therapeutic target
• [Tau Protein](/proteins/tau) — AD/PD therapeutic target
• [Alpha-Synuclein](/proteins/alpha-synuclein) — PD therapeutic target
• [LRRK2](/genes/lrrk2) — PD genetic target
• [GBA](/genes/gba) — PD genetic target
• [SOD1](/genes/sod1) — ALS genetic target
• [C9orf72](/genes/c9orf72) — ALS/FTD genetic target

Mechanism Pathways

• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis) — AD mechanism
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity) — AD/PD mechanism
• [Neuroinflammation](/mechanisms/neuroinflammation) — AD/PD/ALS mechanism
• [Mitophagy Pathway](/mechanisms/mitophagy) — PD mechanism

Related Therapy Ideas

• [Novel Therapy Index](/ideas/novel-therapy-index) — Comprehensive therapy rankings
• [GLP-1 Agonists for Neurodegeneration](/ideas/combo-sirt1-nad-epigenetic-metabolic) — Metabolic therapy

Coverage Gaps

The following areas need additional content or pages:

Uncovered Therapeutic Areas

• PSP (Progressive Supranuclear Palsy): No dedicated therapeutic ideas section
• CBS (Corticobasal Syndrome): No dedicated therapeutic ideas section
• MSA (Multiple System Atrophy): No dedicated therapeutic ideas section
• FTD (Frontotemporal Dementia): Limited therapeutic ideas coverage
• DLB (Dementia with Lewy Bodies): No dedicated therapeutic ideas section

Underdeveloped Categories

• Combination therapies: Limited coverage of multi-target approaches
• Preventive strategies: Minimal content on prevention approaches
• Biomarker-driven therapies: Lacking integration with diagnostic content
• Gene therapy modalities: AAV, ASO, and CRISPR approaches need expansion

Missing Cross-Links

• Links to mechanism pages for each therapeutic approach
• Links to relevant clinical trial pages
• Links to target protein/gene pages

Related Pages

References